A Canadian-led international research team, spearheaded by Dr. Fang Liu at the Centre for Addiction and Mental Health (CAMH) has received nearly $800,000 US ($1,137,868 CAD) in new funding to advance a promising therapy for multiple sclerosis (MS).
New research presented at the 41st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS 2025) demonstrates that ocrelizumab provides superior control of multiple sclerosis (MS) relapses compared with fingolimod, natalizumab, and alemtuzumab.
A major UK study has revealed that the early warning signs of multiple sclerosis (MS) - including pain, mood changes, and neurological symptoms such as numbness and tingling – may appear years before diagnosis and affect all communities in similar ways.
Higher intake of ultra-processed foods (UPFs) may exacerbate disease activity in early multiple sclerosis (MS), according to new research presented at the 41st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS 2025).
New research presented today at the 41st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS 2025) reveals that menopause may significantly influence how multiple sclerosis (MS) first presents in women, as well as the types of associated health conditions they experience.
Why did you receive this email?
You are receiving this email because you subscribed to updates from AZoNetwork UK Ltd. on one of
our websites
and requested to be notified of additional information.
